Kininogen 1. also known as high-molecular-weight kininogen (HMWK), is a plasma glycoprotein involved in the contact activation system, playing critical roles in inflammation, blood coagulation, and blood pressure regulation. It serves as a precursor for bradykinin, a potent vasoactive peptide, and interacts with factors XI and XII in the intrinsic coagulation pathway. Antibodies targeting kininogen 1 have garnered attention in both research and clinical contexts.
In autoimmune diseases, such as anti-phospholipid syndrome (APS) or rheumatoid arthritis, autoantibodies against kininogen 1 are occasionally detected. These antibodies may interfere with kininogen's physiological functions, potentially contributing to thrombotic events or inflammatory pathologies. Researchers also utilize kininogen 1 antibodies as tools to study its role in vascular permeability, angiogenesis, and cancer progression, as kininogen fragments are implicated in tumor microenvironment modulation.
Commercially available antibodies are typically developed in rabbits or mice using purified kininogen 1 antigens. They are employed in immunoassays (e.g., ELISA, Western blot) or immunohistochemistry to quantify kininogen levels in biological samples or map its tissue distribution. Recent studies explore kininogen 1 as a biomarker in cardiovascular diseases or sepsis, further driving antibody-related research. However, cross-reactivity with low-molecular-weight kininogen or degraded fragments remains a technical challenge, necessitating rigorous validation for specificity.